NCT03139916 - Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions

Glioblastoma

Interventions

DRUG

Temozolomide

Temozolomide causes cell death and shrinks and kills the cancer cells

DRUG

Bavituximab

Bavituximab may activate (cause) the immune system to attack the cancer cells

RADIATION

Radiation

Radiation causes cell death and shrinks and kills the cancer cells.

Trial Locations (2)

Dana Farber Cancer Institute, Boston

Massachusetts general Hospital, Boston